Journey Medical Corp
NASDAQ:DERM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (12.1), the stock would be worth $-3.61 (167% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -18 | $5.39 |
0%
|
| Industry Average | 12.1 | $-3.61 |
-167%
|
| Country Average | 19.6 | $-5.86 |
-209%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
$133.1m
|
/ |
Jan 2026
$-8.2m
|
= |
|
|
$133.1m
|
/ |
Dec 2026
$10.3m
|
= |
|
|
$133.1m
|
/ |
Dec 2027
$43.9m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Journey Medical Corp
NASDAQ:DERM
|
146.3m USD | -18 | -12.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
875.9B USD | 30.6 | 42.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
563.9B USD | 22 | 26.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
234.5B GBP | 23.6 | 30.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 12.9 | 19.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
225.3B CHF | 16.2 | 20.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.7B USD | 12.2 | 16.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 970 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.7 | 11.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.7B USD | 10.3 | 20.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121.1B USD | 8.9 | 17.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
Journey Medical Corp
Glance View
Journey Medical Corp. operates as a commercial-stage pharmaceutical company, which engages in developing, acquiring, licensing and commercializing of dermatology products. The company is headquartered in Scottsdale, Arizona and currently employs 90 full-time employees. The company went IPO on 2021-11-12. The company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company provides nine products that help treat and heal common skin conditions, such as Qbrexza, Accutane, Targadox, Ximino, Exelderm Cream and Solution, Ceracade Skin Emulsion, Luxamend Wound Cream, AMZEEQ and ZILXI. Its product Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, which is an oral isotretinoin drug for the treatment of severe recalcitrant severe acne; Targadox, which is an oral doxycycline drug for adjunctive therapy for acne; Ximino, which is an oral minocycline drug for the treatment of moderate to severe acne; Exelderm Cream and Solution is an antifungal intended for topical use; Ceracade Skin Emulsion is used to treat dry skin conditions; AMZEEQ is used for the treatment of acne and ZILXI, for the treatment of rosacea.
